Section of Adult and Pediatric Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Chicago, IL 60637, USA.
Target Oncol. 2011 Dec;6(4):217-26. doi: 10.1007/s11523-011-0197-2. Epub 2011 Nov 19.
In recent years, tyrosine kinase inhibitors (TKIs) have emerged as a new class of anti-cancer therapy with proven efficacy in several types of carcinoma. Although generally considered less toxic than cytotoxic chemotherapy, TKIs do have significant side effects including fatigue and hypertension. In addition, TKI-induced thyroid dysfunction is now recognized as a common toxicity that is associated with some TKI inhibitors. Detection of TKI-induced thyroid dysfunction requires routine monitoring of thyroid function and, in some cases, may require treatment. This review provides a comprehensive assessment of literature evaluating TKI-induced thyroid dysfunction, focusing on the potential mechanisms that result in this toxicity, whether the development of thyroid dysfunction is clinically meaningful, and controversies regarding treatment with thyroid hormone therapy.
近年来，酪氨酸激酶抑制剂（TKIs）作为一类新型的抗癌治疗药物，已在多种癌症中显示出疗效。尽管 TKI 通常被认为比细胞毒性化疗毒性更小，但它们确实有显著的副作用，包括疲劳和高血压。此外，现在已经认识到 TKI 诱导的甲状腺功能障碍是一种常见的毒性，与一些 TKI 抑制剂有关。检测 TKI 诱导的甲状腺功能障碍需要常规监测甲状腺功能，在某些情况下可能需要治疗。本综述全面评估了文献中评估 TKI 诱导的甲状腺功能障碍的研究，重点关注导致这种毒性的潜在机制、甲状腺功能障碍的发展是否具有临床意义，以及甲状腺激素治疗的争议。
